BEVERLY, MA--(Marketwire - June 21, 2010) - Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have concluded more pre-clinical cell studies for Kevetrin, their flagship compound for the treatment of multi-drug resistant strains of lung, breast and colon cancers. The research was conducted on drug resistant non-small cell lung carcinoma cells by the Cellceutix research team at a world-renown cancer hospital in Boston.
The studies were focused on the methods of action with Kevetrin pertaining to the cell life cycle process. Efficient elimination of carcinoma cells requires identifying multi-pathways to treat the affected cells. This research had the purpose of identifying another pathway that Kevetrin may be effective against multi-drug resistant cancer cells. The data compiled from the research showed that Kevetrin had a 78% effective rate of G2/M arrest. The data also showed that cells treated with Kevetrin also demonstrated a 66% increase in apoptosis, defined as a form of cell death, as compared to non-treated cells.
“The G2/M portion of a cancer cell’s cycle is critical as it the stage before a cell enters mitosis, the time when the cell divides into 2 identical nuclei. Kevetrin is proving once again to slow or stop the growth of carcinoma cells,” stated Cellceutix Chief Scientific Officer Dr. Krishna Menon. “The increased apoptosis is very significant because it shows that the cancer cells are being destroyed without damaging any of the healthy cells around it.”
George Evans, CEO of Cellceutix, commented, “This data provides important insight into how Kevetrin is working to attack resistant cancer cells and significant because when dealing with drug-resistant cancers it is imperative to find multiple pathways to destroy the cells.” Mr. Evans continued, “We are very excited about the potential Kevetrin is presenting to the value of our company as all pre-clinical data has been extremely promising.”
About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for drug-resistant cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix’s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix’s actual results to differ from its forward-looking statements include: Cellceutix’s current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix’s ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix’s SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623
Email Contact
